Go to Wolters Kluwer VitalLaw.comGo to Wolters Kluwer VitalLaw.com
VitalLaw®
  • Find answers to your questions
  • Log in to access your subscriptions
In depth. On point.
In depth. On point.
  • Home
  • Legal Directory
  • Home
  • Legal Directory
In depth. On point.
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations
    • FEDERAL LEGISLATION NEWS—Trump signs bill ending partial shutdown, extending telehealth flexibilities
    • ADVERTISING (FOOD, DRUG & MEDICAL DEVICES)—D. N.J.: Article III, Lanham Act standing conferred in ‘compounded semaglutide’ case
    • ANTITRUST—D. Conn.: Settlement reached with Bausch, Lannett, in multi-state antitrust litigation
    • CONTROLLED SUBSTANCES—NOTICES: DEA publishes notice of bulk manufacturer application
    • ELECTRONIC HEALTH RECORDS—S.D. Cal.: Patient’s wiretap claims against LASIK website operator allowed to proceed
    • EXPERT INSIGHTS—DOJ continues to scrutinize medical director arrangements
    • GENERAL HEALTH CARE NEWS—D.D.C.: District judge declines ruling on constitutionality of presidential appointment
    • GENERAL HEALTH CARE NEWS—NOTICES: AHRQ announces voluntary delisting of a PSO
    • MEDICAID—D. Kan.: Court dismisses most of Medicaid recipient’s claims over transportation services
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations

    Health Law Daily Wrap Up, CONTROLLED SUBSTANCES—NOTICES: DEA publishes notice of bulk manufacturer application, (Feb 4, 2026)

    By WK Editorial Staff

    Promega Corporation has applied to be registered as a bulk manufacturer of basic classes of controlled substances.

    The company plans to bulk manufacture the listed controlled substances as active pharmaceutical ingredients for sale to its customers. N ...

    By WK Editorial Staff

    Promega Corporation has applied to be registered as a bulk manufacturer of basic classes of controlled substances.

    The company plans to bulk manufacture the listed controlled substances as active pharmaceutical ingredients for sale to its customers. No other activities for these drug codes are authorized for this registration. Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration (Notice, 91 Fed. Reg. 4634 (Feb. 2, 2026)).

    Dates. Comments on or objections to the issuance of the proposed registration may be submitted on or before April 3, 2026. Written requests for a hearing on the application are also due on or before April 3, 2026.

    FederalRegisterIssuances: Notices ControlledNews GeneralNews

    © 2026 CCH Incorporated and its affiliates and licensors. All rights reserved.

    • Manage Cookie Preferences
    • Privacy Statement
    • Terms of Use